Skip to main content
. 2022 Jun 2;15(4):803–808. doi: 10.1007/s12328-022-01645-1

Table 2.

Patient and treatment characteristics

Sex Age (years) TMN CTx Total dose (Gy) Infield outcome Recurrence TTP (months) OS (months) Ref
Female 61 T3N2M0 EP 50.4 SD R 11 15 >  [13]
Male 56 T3N1M0 5-FU 58.4 PR L + R + DM 5 8 [13]
Male 50 T3N2M0 EP 50/4 CR No 12 >  [13]

T tumor, N node, M metastasis, CTx chemotherapy, EP etoposide and carboplatin, 5-FU 5-fluorouracil, SD stable disease, PR partial response, CR complete response, R regional recurrence, L local recurrence, DM distant metastasis, TTP time to progression, OS overall survival, Ref reference